
# **Product data sheet**



Chemical Formula: C <sub>24</sub> H <sub>26</sub> ClN <sub>3</sub> O <sub>2</sub> S		
Exact Mass: 455.1434		
001		
Powder		
$\geq$ 98%		
Ambient temperature		
Powder: -20°C 3 years; 4°C 2 years.		
In solvent: -80°C 3 months; -20°C 2 weeks.		
	001 Powder $\geq 98\%$ Ambient temperature Powder: -20°C 3 years; 4°C 2 years.	



# 1. Product description:

HZ-52 is a potent, reversible inhibitor of 5-lipoxygenase that blocks leukotriene synthesis in polymorphonuclear leukocytes. HZ-52 also attenuates leukotriene B4 synthesis, prevents carrageenan-induced pleurisy, and protects against platelet-activating factor-induced shock.

# 2. CoA, QC data, SDS, and handling instruction

SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under "QC And Documents" section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

# 3. Solubility data

er solusing unu				
Solvent	Max Conc. mg/mL	Max Conc. mM		
DMF	30.0	65.79		
DMF:PBS (pH 7.2)	0.1	0.22		
(1:9)				
DMSO	20.0	43.86		
Ethanol	10.0	21.93		

# 4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.19 mL	10.96 mL	21.93 mL
5 mM	0.44 mL	2.19 mL	4.39 mL
10 mM	0.22 mL	1.10 mL	2.19 mL
50 mM	0.04 mL	0.22 mL	0.44 mL

# 5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator

Please refer the product web page under section of "Calculator"

# 6. Recommended literature which reported protocols for in vitro and in vivo study

In vitro study

1. Greiner C, Hörnig C, Rossi A, Pergola C, Zettl H, Schubert-Zsilavecz M, Steinhilber D, Sautebin L, Werz O. 2-(4-(Biphenyl-4-ylamino)-6-chloropyrimidin-2-ylthio)octanoic acid (HZ52)--a novel type of 5-lipoxygenase inhibitor with favourable molecular pharmacology and efficacy in vivo. Br J Pharmacol. 2011 Sep;164(2b):781-93. doi: 10.1111/j.1476-5381.2011.01451.x. PMID: 21506958; PMCID: PMC3188909.

#### In vivo study

1. Greiner C, Hörnig C, Rossi A, Pergola C, Zettl H, Schubert-Zsilavecz M, Steinhilber D, Sautebin L, Werz O. 2-(4-(Biphenyl-4-ylamino)-6-chloropyrimidin-2-ylthio)octanoic acid (HZ52)--a novel type of 5-lipoxygenase inhibitor with favourable molecular pharmacology and efficacy in vivo. Br J Pharmacol. 2011 Sep;164(2b):781-93. doi: 10.1111/j.1476-5381.2011.01451.x. PMID: 21506958; PMCID: PMC3188909.

# 7. Bioactivity

# **Product data sheet**



#### **Biological target:**

A reversible inhibitor of 5-lipoxygenase.

### In vitro activity

In accordance with this study's previous findings (Koeberle *et al.*, 2008), HZ52 inhibited 5-LO product synthesis in human PMNL stimulated with the Ca<sup>2+</sup> ionophore A23187 (2.5  $\mu$ M) plus AA (20  $\mu$ M) with an IC<sub>50</sub> = 0.7  $\mu$ M for both LTB<sub>4</sub> and 5-H(P)ETE (Figure 1B).

Reference: Br J Pharmacol. 2011 Sep;164(2b):781-93. https://pubmed.ncbi.nlm.nih.gov/21506958/

### In vivo activity

HZ52, 1.5 mg·kg<sup>-1</sup> i.p., prevented carrageenan-induced pleurisy accompanied by reduced LTB(4) levels and protected mice (10 mg·kg<sup>-1</sup>, i.p.) against PAF-induced shock.

Reference: Br J Pharmacol. 2011 Sep;164(2b):781-93. https://pubmed.ncbi.nlm.nih.gov/21506958/

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.